Enhanced allograft survival by combined active and passive immunization: Requirement of both erythrocytes and leukocytes

William M. Baldwin, William L. Null, Jean Notis-McConarty, Nicholas L. Tilney

Research output: Contribution to journalArticle

Abstract

(L × BN)F1 skin and heart allografts survive about 7 days in unmodified L hosts. Their survival is only prolonged modestly by active immunization with LBN splenocytes or passive immunization with hyperimmune serum, but the combination of active and passive immunization produces dramatic improvement in graft survival. When the components of this synergistic interaction were analyzed, it was found that not only were lymphocyte-borne antigens and antibodies directed against these antigens important, but also that erythrocyte-borne serologically determined antigens and anti-erythrocyte antibodies were required for optimal survival of both skin and heart allografts. Furthermore, thymic or lymph node cells supplemented with erythrocytes were as effective a source of antigen as whole spleen in prolonging graft survival. These data indicate that, in allograft models in rats, antigens and antibodies that may be of minor importance in producing enhancement when administered individually may be more important when administered together. The underlying basis for the increased effectiveness of erythrocyte-borne antigens and anti-erythrocyte antibodies may be related to the observation that the injected erythrocytes remain in the allogeneic host's circulation to interact with the subsequent i.v. injection of antisera to form soluble antigen-antibody complexes.

Original languageEnglish (US)
Pages (from-to)121-125
Number of pages5
JournalTransplantation
Volume25
Issue number3
StatePublished - 1978
Externally publishedYes

Fingerprint

Passive Immunization
Allografts
Vaccination
Leukocytes
Erythrocytes
Antigens
Graft Survival
Anti-Idiotypic Antibodies
Skin
Antibodies
Antigen-Antibody Complex
Immune Sera
Spleen
Lymph Nodes
Lymphocytes
Injections
Serum

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Baldwin, W. M., Null, W. L., Notis-McConarty, J., & Tilney, N. L. (1978). Enhanced allograft survival by combined active and passive immunization: Requirement of both erythrocytes and leukocytes. Transplantation, 25(3), 121-125.

Enhanced allograft survival by combined active and passive immunization : Requirement of both erythrocytes and leukocytes. / Baldwin, William M.; Null, William L.; Notis-McConarty, Jean; Tilney, Nicholas L.

In: Transplantation, Vol. 25, No. 3, 1978, p. 121-125.

Research output: Contribution to journalArticle

Baldwin, WM, Null, WL, Notis-McConarty, J & Tilney, NL 1978, 'Enhanced allograft survival by combined active and passive immunization: Requirement of both erythrocytes and leukocytes', Transplantation, vol. 25, no. 3, pp. 121-125.
Baldwin, William M. ; Null, William L. ; Notis-McConarty, Jean ; Tilney, Nicholas L. / Enhanced allograft survival by combined active and passive immunization : Requirement of both erythrocytes and leukocytes. In: Transplantation. 1978 ; Vol. 25, No. 3. pp. 121-125.
@article{023c153aaf384c12bf13f63b36bfa981,
title = "Enhanced allograft survival by combined active and passive immunization: Requirement of both erythrocytes and leukocytes",
abstract = "(L × BN)F1 skin and heart allografts survive about 7 days in unmodified L hosts. Their survival is only prolonged modestly by active immunization with LBN splenocytes or passive immunization with hyperimmune serum, but the combination of active and passive immunization produces dramatic improvement in graft survival. When the components of this synergistic interaction were analyzed, it was found that not only were lymphocyte-borne antigens and antibodies directed against these antigens important, but also that erythrocyte-borne serologically determined antigens and anti-erythrocyte antibodies were required for optimal survival of both skin and heart allografts. Furthermore, thymic or lymph node cells supplemented with erythrocytes were as effective a source of antigen as whole spleen in prolonging graft survival. These data indicate that, in allograft models in rats, antigens and antibodies that may be of minor importance in producing enhancement when administered individually may be more important when administered together. The underlying basis for the increased effectiveness of erythrocyte-borne antigens and anti-erythrocyte antibodies may be related to the observation that the injected erythrocytes remain in the allogeneic host's circulation to interact with the subsequent i.v. injection of antisera to form soluble antigen-antibody complexes.",
author = "Baldwin, {William M.} and Null, {William L.} and Jean Notis-McConarty and Tilney, {Nicholas L.}",
year = "1978",
language = "English (US)",
volume = "25",
pages = "121--125",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Enhanced allograft survival by combined active and passive immunization

T2 - Requirement of both erythrocytes and leukocytes

AU - Baldwin, William M.

AU - Null, William L.

AU - Notis-McConarty, Jean

AU - Tilney, Nicholas L.

PY - 1978

Y1 - 1978

N2 - (L × BN)F1 skin and heart allografts survive about 7 days in unmodified L hosts. Their survival is only prolonged modestly by active immunization with LBN splenocytes or passive immunization with hyperimmune serum, but the combination of active and passive immunization produces dramatic improvement in graft survival. When the components of this synergistic interaction were analyzed, it was found that not only were lymphocyte-borne antigens and antibodies directed against these antigens important, but also that erythrocyte-borne serologically determined antigens and anti-erythrocyte antibodies were required for optimal survival of both skin and heart allografts. Furthermore, thymic or lymph node cells supplemented with erythrocytes were as effective a source of antigen as whole spleen in prolonging graft survival. These data indicate that, in allograft models in rats, antigens and antibodies that may be of minor importance in producing enhancement when administered individually may be more important when administered together. The underlying basis for the increased effectiveness of erythrocyte-borne antigens and anti-erythrocyte antibodies may be related to the observation that the injected erythrocytes remain in the allogeneic host's circulation to interact with the subsequent i.v. injection of antisera to form soluble antigen-antibody complexes.

AB - (L × BN)F1 skin and heart allografts survive about 7 days in unmodified L hosts. Their survival is only prolonged modestly by active immunization with LBN splenocytes or passive immunization with hyperimmune serum, but the combination of active and passive immunization produces dramatic improvement in graft survival. When the components of this synergistic interaction were analyzed, it was found that not only were lymphocyte-borne antigens and antibodies directed against these antigens important, but also that erythrocyte-borne serologically determined antigens and anti-erythrocyte antibodies were required for optimal survival of both skin and heart allografts. Furthermore, thymic or lymph node cells supplemented with erythrocytes were as effective a source of antigen as whole spleen in prolonging graft survival. These data indicate that, in allograft models in rats, antigens and antibodies that may be of minor importance in producing enhancement when administered individually may be more important when administered together. The underlying basis for the increased effectiveness of erythrocyte-borne antigens and anti-erythrocyte antibodies may be related to the observation that the injected erythrocytes remain in the allogeneic host's circulation to interact with the subsequent i.v. injection of antisera to form soluble antigen-antibody complexes.

UR - http://www.scopus.com/inward/record.url?scp=0018239554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018239554&partnerID=8YFLogxK

M3 - Article

C2 - 347646

AN - SCOPUS:0018239554

VL - 25

SP - 121

EP - 125

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -